In addition, we demonstrated increased sensitivity to a PARP inhibitor in a CTC culture derived from a patient with a pathogenic somatic BRCA1 mutation, highlighting the unique role of PARP inhibition for patients with somatic BRCA1/2 mutant breast cancer. The gene discussed is BRCA1; the disease is breast cancer.